HeartFlow Chief Financial Officer Acquires Over 22,000 Shares in Open Market Transaction

CFO Share Acquisition and Equity Grant Details

On July 21, 2026, HeartFlow disclosed that its Chief Financial Officer, Vikram Verghese, acquired 22,522 shares of common stock through an open market purchase at $2.22 per share. The transaction was reported in a regulatory update filed on July 23, 2026. This acquisition represents a significant equity commitment by a senior executive at the cardiovascular diagnostics technology company, which develops artificial intelligence-powered coronary artery disease assessment solutions for clinical use.

In conjunction with the share purchase, Verghese received a stock option grant covering 22,522 shares at an exercise price of $2.22 per share. The options are subject to monthly vesting provisions with a final vesting date of October 30, 2027, provided that Verghese continues his employment with HeartFlow through each applicable vesting date. The options expire on December 24, 2033, providing a seven-year window for exercise following full vesting.

Executive Beneficial Ownership Position Post-Transaction

Following the completion of the open market purchase on July 21, 2026, Verghese's direct beneficial ownership of HeartFlow common stock totaled 233,376 shares. This position is held in direct ownership form rather than through any indirect investment vehicle or trust arrangement. The acquisition adds to the CFO's existing stake in the company, reflecting an increased financial interest in HeartFlow's operational and financial performance going forward.

The executive's expanded equity position comes at a time when HeartFlow continues to operate in the competitive medical technology sector, where artificial intelligence-driven diagnostic platforms are reshaping clinical decision-making for cardiovascular disease assessment. Senior executive equity ownership often signals management confidence in the company's strategic direction and long-term value creation potential, though such transactions do not necessarily predict future share price performance.

Vesting Schedule and Option Exercise Framework

The stock options granted to Verghese on July 21, 2026, incorporate a monthly vesting schedule that extends through October 30, 2027. This structure means the options become exercisable in installments over a 16-month period rather than vesting immediately or on a single future date. The monthly vesting approach ties the executive's option realization to his continued service with HeartFlow, aligning his compensation interests with sustained tenure and performance.

With an exercise price of $2.22 per share—matching the price at which Verghese purchased the underlying common shares—the option grant provides potential upside should HeartFlow's stock price appreciate above that level. The December 24, 2033, expiration date gives Verghese a full seven years from the grant date to exercise the options after they fully vest, providing substantial flexibility in execution timing. Equity compensation structures of this type are common in technology and healthcare companies seeking to retain senior financial leadership.

Regulatory Disclosure and Filing Requirements

The transaction was reported pursuant to Section 16(a) of the Securities Exchange Act of 1934, which requires officers, directors, and substantial shareholders of public companies to disclose changes in beneficial ownership. Verghese's status as an officer—specifically as Chief Financial Officer—triggers mandatory reporting obligations for all equity transactions. The disclosure was filed on July 23, 2026, two business days after the July 21 transaction date, falling within the standard regulatory reporting window.

Form 4 reports provide investors and the market with transparent information about insider trading activity, helping detect potential conflicts of interest, evaluate management confidence levels, and monitor the equity structure of public companies. The detailed tables within the report separate non-derivative securities (the common stock purchase) from derivative securities (the options), enabling precise tracking of different ownership interests and their terms. This transparency supports market integrity and allows investors to make fully informed decisions about company securities.

HeartFlow's Business Model and Market Position

HeartFlow develops and commercializes artificial intelligence-powered diagnostic solutions designed to assess coronary artery disease risk and guide clinical treatment decisions. The company's primary product offering uses advanced imaging analysis and computational modeling to provide detailed cardiovascular diagnostics without invasive procedures, addressing a significant clinical need in cardiology practice. HeartFlow operates in the broader medical technology and diagnostics sector, competing with traditional imaging modalities and emerging AI-based diagnostic platforms.

The company's revenue model is centered on licensing its proprietary AI platform to healthcare institutions, diagnostic imaging centers, and hospital networks, with typical transactions involving upfront licensing fees, software maintenance agreements, and usage-based components. Verghese's acquisition of additional shares and acceptance of option compensation suggests management's perspective that HeartFlow's technological capabilities and market opportunities support long-term shareholder value creation, though past performance and equity compensation do not guarantee future results.

Transaction Code and Market Execution Details

The purchase was executed under transaction code "M," which under Securities and Exchange Commission Form 4 instructions typically indicates an open market or other unspecified purchase. The classification distinguishes this transaction from restricted stock grants, exercises of existing options, or other equity compensation mechanisms. The $2.22 per share purchase price and matching option exercise price indicate that both the common stock acquisition and the option grant were valued at the same rate, which may reflect the stock's market price on July 21, 2026.

No special contractual arrangements, pricing agreements, or Rule 10b5-1 trading plans were noted in the disclosure, suggesting the purchase was executed as a standard open market transaction initiated by the executive. This type of insider acquisition is distinct from company-sponsored buyback programs or coordinated employee stock purchase plans, representing instead a direct market purchase by the executive using his own capital or company compensation arrangements.

Investor Considerations and Monitoring Points

Insider share acquisitions can offer investors one data point for assessing management confidence in future company performance, though such transactions should be evaluated alongside broader financial metrics, competitive positioning, and industry dynamics. Verghese's purchase at $2.22 per share—an amount that may reflect current market pricing—provides context for investors tracking HeartFlow's stock valuation and executive sentiment regarding fair value. Increases in beneficial ownership by senior officers like the Chief Financial Officer may indicate management's belief in the company's strategic trajectory, but historical insider transactions do not predict future stock performance.

Investors monitoring HeartFlow should track subsequent insider trading activity, quarterly financial results, product development announcements, and competitive developments in the AI-powered diagnostics sector. The company's ability to expand its customer base, demonstrate clinical efficacy of its platform, and maintain technological differentiation in a rapidly evolving market will significantly influence shareholder returns regardless of individual insider equity transactions. Regulatory filings such as this one provide transparency but represent only one component of comprehensive investment analysis.

Options Vesting Mechanics and Retention Incentives

The monthly vesting schedule for Verghese's 22,522 options serves a dual purpose: it provides long-term equity incentive compensation while functionally requiring the CFO's continued employment through the vesting period. By tying option accessibility to sustained service rather than granting them fully vested, HeartFlow structures its compensation to encourage retention of senior financial leadership. If Verghese were to depart the company prior to October 30, 2027, unvested options would typically be forfeited, creating direct financial consequences for early termination.

This retention mechanism reflects common practices in technology and healthcare companies, where experienced finance executives are viewed as critical to operational success and capital allocation strategy. The 16-month vesting window is relatively shorter than some executive compensation structures, which might extend over three to four years, suggesting either a new hire retention package or a refresher grant to an existing executive. The structure balances the executive's interest in near-term equity realization against the company's interest in maintaining continuity in its Chief Financial Officer position during a period of operational execution.